Study of Dark Adaptation in Age-Related Macular Degeneration
NCT ID: NCT01352975
Last Updated: 2025-12-08
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
ACTIVE_NOT_RECRUITING
Total Enrollment
217 participants
Study Classification
OBSERVATIONAL
Study Start Date
2011-05-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Background:
* Age-related macular degeneration (AMD) is a leading cause of vision loss in individuals over 55 years of age. It can cause permanent loss of central vision, which is important for seeing fine details and long distances. AMD has two forms: wet AMD and dry AMD. Most people with AMD have dry AMD. But dry AMD can progress to wet AMD. Wet AMD is the more serious form and can result in severe vision loss.
* A method to identify and monitor the early to middle stages of AMD may help researchers develop new treatments to stop the disease before it becomes severe. In early dry AMD, people cannot see well at night. Researchers want to study whether a procedure that measures how the eye adjusts to the dark can help to identify and monitor early to middle dry AMD.
Objectives:
\- To evaluate the effectiveness of using a dark adaptation protocol to identify and monitor early to middle dry age-related macular degeneration.
Eligibility:
\- People at least 50 years of age who have no AMD. Others who have early to middle dry AMD in at least one eye.
Design:
* People will be screened with a physical examination, medical history, blood and urine tests, and a full eye exam.
* This study will last 5 years and require at least 9 visits to NIH. (First visit; study visits at months 3, 6, 12, 18, and 24; and 3 yearly followup visits).
* Up to 10 people will be asked to come back to the clinic 1 week after their first visit. They will be asked to test the device to be used in the study.
* Participants will have baseline exams. These questions will be about problems that affect their eyes under different lighting conditions.
* At every visit, participants will answer questions about general health and current medications (including any vitamins or supplements). They will also have a full eye exam and a 20- to 40-minute test. This test measures how fast the eyes recover in response to decreasing levels of light. The test also measures how sensitive the eyes are to these conditions.
* Participants will continue to have these tests at the yearly followup examinations. They will be treated with the standard of care for any eye conditions they have or may develop during the study.
* Age-related macular degeneration (AMD) is a leading cause of vision loss in individuals over 55 years of age. It can cause permanent loss of central vision, which is important for seeing fine details and long distances. AMD has two forms: wet AMD and dry AMD. Most people with AMD have dry AMD. But dry AMD can progress to wet AMD. Wet AMD is the more serious form and can result in severe vision loss.
* A method to identify and monitor the early to middle stages of AMD may help researchers develop new treatments to stop the disease before it becomes severe. In early dry AMD, people cannot see well at night. Researchers want to study whether a procedure that measures how the eye adjusts to the dark can help to identify and monitor early to middle dry AMD.
Objectives:
\- To evaluate the effectiveness of using a dark adaptation protocol to identify and monitor early to middle dry age-related macular degeneration.
Eligibility:
\- People at least 50 years of age who have no AMD. Others who have early to middle dry AMD in at least one eye.
Design:
* People will be screened with a physical examination, medical history, blood and urine tests, and a full eye exam.
* This study will last 5 years and require at least 9 visits to NIH. (First visit; study visits at months 3, 6, 12, 18, and 24; and 3 yearly followup visits).
* Up to 10 people will be asked to come back to the clinic 1 week after their first visit. They will be asked to test the device to be used in the study.
* Participants will have baseline exams. These questions will be about problems that affect their eyes under different lighting conditions.
* At every visit, participants will answer questions about general health and current medications (including any vitamins or supplements). They will also have a full eye exam and a 20- to 40-minute test. This test measures how fast the eyes recover in response to decreasing levels of light. The test also measures how sensitive the eyes are to these conditions.
* Participants will continue to have these tests at the yearly followup examinations. They will be treated with the standard of care for any eye conditions they have or may develop during the study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Development of a Device to Measure Dark Adaptation
NCT02090751
Macular Degeneration
Age-Related Macular Degeneration
COMPLETED
Natural History of Geographic Atrophy Associated With Age-Related Macular Degeneration
NCT02941263
Age-Related Macular Degeneration
COMPLETED
Functional and Anatomical Visual Investigations in Patients With Early Forms of Age-related Macular Degeneration
NCT06694272
Age Related Macular Degeneration
RECRUITING
Study on Visual Function Impairments in Dry Age-related Macular Degeneration
NCT01822873
Age Related Macular Degeneration
COMPLETED
AMD and Validation Rod-Meditated Dark Adaptation With Everyday Task Performance
NCT06619405
Age-Related Macular Degeneration
RECRUITING
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Objective: This study is designed to investigate the use of dark adaptation as a functional endpoint for progression of eyes with no to intermediate age-related macular degeneration (AMD). To that aim, correlating structural features (obtained from multimodal imaging) as well as genetic and systemic factors obtained from biospecimens with functional measures (including dark adaptation, visual acuity and low luminance) will be done to understand the relationship of disease relevant factors and to create a model of disease pathogenesis and progression.
Study Population: Two hundred forty (240) participants will be initially accrued; however, up to 280 participants who meet the eligibility criteria may be enrolled. Participants will have varying degrees of severity of AMD (Groups 0, 1, 2, 3 and 4). Group 0 (N=40) is defined as participants without AMD meaning no large drusen (\>= 125 microns) or advanced AMD in either eye. Group 1 (N=40) is defined as participants with large drusen (\>= 125 microns) in the study eye and no large drusen or advanced AMD (choroidal neovascularization (CNV) or geographic atrophy (GA)) in the fellow eye. Group 2 (N=40) is defined as participants with bilateral large drusen (\>= 125 microns) with or without retinal pigment epithelial hypo/hyperpigmentary changes. Group 3 (N=40) is defined as participants with large drusen (\>= 125 microns) in the study eye and advanced AMD (CNV or GA) in the fellow eye. Group 4 (N=40) is defined as participants with findings of reticular pseudodrusen (RPD) defined as having (1) the presence of reticular inter-lacing patterns on at least one en face imaging method (color photography, autofluorescence or infrared) and (2) confirmation of previously described findings of hyperreflective material located between the retinal pigment epithelium (RPE) and the photoreceptor ellipsoid zone on SD OCT in those areas. Current participants in this study have been graded and categorized into this cohort. Up to 40 diabetic participants will be recruited.
Design: This is a single center, exploratory, observational, longitudinal evaluation of dark adaptation response in AMD participants over five years and long-term evaluation of dark adaptometry (DA) change as a predictor for AMD progression and visual acuity (VA) loss.
Outcome Measures: The primary outcome is to determine mean change, including the distribution of change, in dark adaptation response between baseline and months 12 and 24 for Groups 0, 1, 2, 3 and 4. The secondary outcomes for each of the five groups are to determine mean change in dark adaptation response from baseline at months 3, 6, 18, 36, 48 and 60 and to determine mean change in best-corrected visual acuity (BCVA) of the study eye from baseline at months 3, 6, 12, 18, 24, 36, 48 and 60. Exploratory outcomes for each of the five groups are to correlate mean BCVA of the study eye with mean dark adaptation response at baseline and months 3, 6, 12, 18, 24, 36, 48 and 60 and to correlate AMD severity, including grading by an external Reading Center, with dark adaptation response at baseline and months 3, 6, 12, 18, 24, 36, 48 and 60. Images from all visits may be sent to the Reading Center; however, only the baseline and annual visits are required to be graded. This study will also analyze renal function in AMD participants. Additionally, exploratory analysis of the small sample of diabetic participants will also be performed.
Outcome measures for the genetic testing and RNA sequencing performed on participants co-enrolled in the Biobank protocol (12-EI-0042) include the interaction of key parameters of phenotype (such as visual acuity, dark adaptation, and retinal features on ocular imaging) with genetic variants and other biomarkers identified from biospecimens, and the characterization of new experimental models of eye health and disease.
Study Population: Two hundred forty (240) participants will be initially accrued; however, up to 280 participants who meet the eligibility criteria may be enrolled. Participants will have varying degrees of severity of AMD (Groups 0, 1, 2, 3 and 4). Group 0 (N=40) is defined as participants without AMD meaning no large drusen (\>= 125 microns) or advanced AMD in either eye. Group 1 (N=40) is defined as participants with large drusen (\>= 125 microns) in the study eye and no large drusen or advanced AMD (choroidal neovascularization (CNV) or geographic atrophy (GA)) in the fellow eye. Group 2 (N=40) is defined as participants with bilateral large drusen (\>= 125 microns) with or without retinal pigment epithelial hypo/hyperpigmentary changes. Group 3 (N=40) is defined as participants with large drusen (\>= 125 microns) in the study eye and advanced AMD (CNV or GA) in the fellow eye. Group 4 (N=40) is defined as participants with findings of reticular pseudodrusen (RPD) defined as having (1) the presence of reticular inter-lacing patterns on at least one en face imaging method (color photography, autofluorescence or infrared) and (2) confirmation of previously described findings of hyperreflective material located between the retinal pigment epithelium (RPE) and the photoreceptor ellipsoid zone on SD OCT in those areas. Current participants in this study have been graded and categorized into this cohort. Up to 40 diabetic participants will be recruited.
Design: This is a single center, exploratory, observational, longitudinal evaluation of dark adaptation response in AMD participants over five years and long-term evaluation of dark adaptometry (DA) change as a predictor for AMD progression and visual acuity (VA) loss.
Outcome Measures: The primary outcome is to determine mean change, including the distribution of change, in dark adaptation response between baseline and months 12 and 24 for Groups 0, 1, 2, 3 and 4. The secondary outcomes for each of the five groups are to determine mean change in dark adaptation response from baseline at months 3, 6, 18, 36, 48 and 60 and to determine mean change in best-corrected visual acuity (BCVA) of the study eye from baseline at months 3, 6, 12, 18, 24, 36, 48 and 60. Exploratory outcomes for each of the five groups are to correlate mean BCVA of the study eye with mean dark adaptation response at baseline and months 3, 6, 12, 18, 24, 36, 48 and 60 and to correlate AMD severity, including grading by an external Reading Center, with dark adaptation response at baseline and months 3, 6, 12, 18, 24, 36, 48 and 60. Images from all visits may be sent to the Reading Center; however, only the baseline and annual visits are required to be graded. This study will also analyze renal function in AMD participants. Additionally, exploratory analysis of the small sample of diabetic participants will also be performed.
Outcome measures for the genetic testing and RNA sequencing performed on participants co-enrolled in the Biobank protocol (12-EI-0042) include the interaction of key parameters of phenotype (such as visual acuity, dark adaptation, and retinal features on ocular imaging) with genetic variants and other biomarkers identified from biospecimens, and the characterization of new experimental models of eye health and disease.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Age-Related Macular Degeneration
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 0
participants without AMD (no large drusen or advanced AMD in either eye)
No interventions assigned to this group
Group 1
participants with large drusen in study eye and no large drusen or advanced AMD or GA in fellow eye
No interventions assigned to this group
Group 2
participants with bilateral large drusen with or without retinal pigment epithelial hypo/hyperpigmentary changes
No interventions assigned to this group
Group 3
participants with large drusen in study eye and advanced AMD (CNV and GA) in fellow eye
No interventions assigned to this group
Group 4
participants with findings of RPD
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participant is able to understand and sign the protocol s informed consent document.
* Participant is able to complete and comply with study assessments for the full duration of the study.
* Participant is \>= 50 years of age.
* Participant has a BCVA score of \>= 20/100 (Snellen equivalent) in study eye.
* Participant qualifies for one of the following groups based on AMD grading as defined below.
* Group 0: Participant without AMD defined as no large drusen or advanced AMD in either eye;
* Group 1: Participant has at least one large drusen (\>= 125 microns) in the study eye and no large drusen or advanced AMD in the fellow eye;
* Group 2: Participant has bilateral large drusen (\>= 125 microns) with or without retinal pigment epithelial hypo/hyperpigmentary changes;
* Group 3: Participant has at least one large drusen (\>= 125 microns) in the study eye and advanced AMD in the fellow eye.
* Group 4: Participant has reticular pseudodrusen in the study eye defined as having (1) the presence of RPD on at least one en face imaging method (color photography, autofluorescence or infrared) and (2) confirmation of previously described findings of hyperreflective material located between the RPE and the photoreceptor ellipsoid zone on SD OCT in those areas.
* Participant is able to complete and comply with study assessments for the full duration of the study.
* Participant is \>= 50 years of age.
* Participant has a BCVA score of \>= 20/100 (Snellen equivalent) in study eye.
* Participant qualifies for one of the following groups based on AMD grading as defined below.
* Group 0: Participant without AMD defined as no large drusen or advanced AMD in either eye;
* Group 1: Participant has at least one large drusen (\>= 125 microns) in the study eye and no large drusen or advanced AMD in the fellow eye;
* Group 2: Participant has bilateral large drusen (\>= 125 microns) with or without retinal pigment epithelial hypo/hyperpigmentary changes;
* Group 3: Participant has at least one large drusen (\>= 125 microns) in the study eye and advanced AMD in the fellow eye.
* Group 4: Participant has reticular pseudodrusen in the study eye defined as having (1) the presence of RPD on at least one en face imaging method (color photography, autofluorescence or infrared) and (2) confirmation of previously described findings of hyperreflective material located between the RPE and the photoreceptor ellipsoid zone on SD OCT in those areas.
Exclusion Criteria
Participants who meet any of the following criteria will be excluded from this study:
* Participant has advanced AMD in the study eye at the baseline visit.
* Participant has other active ocular or macular diseases (e.g., diabetic macular edema, retinal vein occlusion, Stargardt's disease or cone-rod dystrophy) or other known ocular disorders that have caused a visual field deficit (e.g., glaucoma with known visual field defect) in the study eye.
* Participant has a fixation deficit in the study eye that would prevent the participant from performing the AdaptDxTM dark adaptation protocol.
* Participant has a medical condition that the investigator feels would prevent the participant from complying with or being able to complete the study assessments.
* Participant had cataract surgery in the study eye within three months prior to enrollment.
* Participant has an oral intake of high doses of vitamin A palmitate supplement (\>= 10,000 international units (IU) per day).
* Participant has or had hepatitis or liver disease. Abnormally low vitamin A can alter dark adaptation and chronic liver disease has been associated with low vitamin A.
* Participant has a history of vitamin A deficiency.
* Participant is an NEI employee or subordinate or co-worker of an investigator.
* Participant has advanced AMD in the study eye at the baseline visit.
* Participant has other active ocular or macular diseases (e.g., diabetic macular edema, retinal vein occlusion, Stargardt's disease or cone-rod dystrophy) or other known ocular disorders that have caused a visual field deficit (e.g., glaucoma with known visual field defect) in the study eye.
* Participant has a fixation deficit in the study eye that would prevent the participant from performing the AdaptDxTM dark adaptation protocol.
* Participant has a medical condition that the investigator feels would prevent the participant from complying with or being able to complete the study assessments.
* Participant had cataract surgery in the study eye within three months prior to enrollment.
* Participant has an oral intake of high doses of vitamin A palmitate supplement (\>= 10,000 international units (IU) per day).
* Participant has or had hepatitis or liver disease. Abnormally low vitamin A can alter dark adaptation and chronic liver disease has been associated with low vitamin A.
* Participant has a history of vitamin A deficiency.
* Participant is an NEI employee or subordinate or co-worker of an investigator.
Minimum Eligible Age
50 Years
Maximum Eligible Age
100 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Eye Institute (NEI)
NIH
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Emily Y Chew, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Eye Institute (NEI)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Hess K, de Silva T, Grisso P, Wiley H, Thavikulwat AT, Keenan TDL, Chew EY, Cukras CA. Evaluation of Cone- and Rod-Mediated Parameters in Dark Adaptation Testing as Outcome Measures in Age-Related Macular Degeneration. Ophthalmol Retina. 2022 Dec;6(12):1173-1184. doi: 10.1016/j.oret.2022.05.018. Epub 2022 May 26.
Reference Type
DERIVED
Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984 Nov;102(11):1640-2. doi: 10.1001/archopht.1984.01040031330019.
Reference Type
BACKGROUND
Friedman DS, O'Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J; Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004 Apr;122(4):564-72. doi: 10.1001/archopht.122.4.564.
Reference Type
BACKGROUND
Scilley K, Jackson GR, Cideciyan AV, Maguire MG, Jacobson SG, Owsley C. Early age-related maculopathy and self-reported visual difficulty in daily life. Ophthalmology. 2002 Jul;109(7):1235-42. doi: 10.1016/s0161-6420(02)01060-6.
Reference Type
BACKGROUND
Grune T, Lietz G, Palou A, Ross AC, Stahl W, Tang G, Thurnham D, Yin SA, Biesalski HK. Beta-carotene is an important vitamin A source for humans. J Nutr. 2010 Dec;140(12):2268S-2285S. doi: 10.3945/jn.109.119024. Epub 2010 Oct 27.
Reference Type
BACKGROUND
Duic C, Pfau K, Keenan TDL, Wiley H, Thavikulwat A, Chew EY, Cukras C. Hyperreflective Foci in Age-Related Macular Degeneration are Associated with Disease Severity and Functional Impairment. Ophthalmol Retina. 2023 Apr;7(4):307-317. doi: 10.1016/j.oret.2022.11.006. Epub 2022 Nov 17.
Reference Type
DERIVED
Yazdanie M, Alvarez J, Agron E, Wong WT, Wiley HE, Ferris FL 3rd, Chew EY, Cukras C. Decreased Visual Function Scores on a Low Luminance Questionnaire Is Associated with Impaired Dark Adaptation. Ophthalmology. 2017 Sep;124(9):1332-1339. doi: 10.1016/j.ophtha.2017.05.005. Epub 2017 Jun 8.
Reference Type
DERIVED
Related Links
Access external resources that provide additional context or updates about the study.
https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2011-EI-0147.html
NIH Clinical Center Detailed Web Page
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
11-EI-0147
Identifier Type: -
Identifier Source: secondary_id
110147
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Project AMD: Comprehensive Characterisation of Age-Related Macular Degeneration and Its Progression
NCT04739319
RECRUITING
Progression of Early Atrophic Lesions
NCT05959005
RECRUITING
Comparison of Cytokine Profiles in Aqueous Humor of Patients With Age Related Macular Degeneration (AMD)
NCT03418220
COMPLETED
NA
Therapy of Age-related Macular Degeneration
NCT05222997
UNKNOWN
An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration
NCT05300724
ACTIVE_NOT_RECRUITING
Implication of CD35, CD21 and CD55 in Exudative Age-related Macular Degeneration
NCT01174407
UNKNOWN
Ocular, Vascular, and Genetic Findings in AMD Patients
NCT06015633
ACTIVE_NOT_RECRUITING
The Impact of Artificial Lighting on the Visual Capacity of Patients With Age-Related Macular Degeneration
NCT07060196
NOT_YET_RECRUITING
Choroidal Blood Flow and Progression of Age-Related Macular Degeneration in the Fellow Eye in Patients With Unilateral Choroidal Neovascularisation
NCT00808197
COMPLETED
NA
Intermediate Age-related Macular Degeneration - Multimodal Analysis and Longitudinal Study
NCT06355830
RECRUITING
Colour Contrast Sensitivity for the Early Detection of Wet Age-related Macular Degereration (CEDAR)
NCT02173496
COMPLETED
Recurrence and Predictive OCT Biomarkers in Quiescent Neovascular AMD
NCT06717139
ACTIVE_NOT_RECRUITING
AMD Phenotype and Genotype Study
NCT01778491
COMPLETED
Telemedicine in Age-Related Macular Degeneration
NCT04863391
UNKNOWN
Survival of Monocytes Collected From Patients With Atrophic AMD in Retinal Pigmented Epithelium Explants
NCT04697095
RECRUITING
NA
Direct Discrimination of Quantum States by the Human Eye
NCT05913063
RECRUITING
NA
Non Exudative AMD Imaged With SS-OCT
NCT03688243
UNKNOWN
Identification and Treatment of Feeder Vessels in Macular Degeneration
NCT00018070
COMPLETED
PHASE1
Non Exudative AMD Imaged With SS-OCT- Extension
NCT04469140
UNKNOWN
Deciphering AMD by Deep Phenotyping and Machine Learning- Prospective Study - PINNACLE
NCT04269304
ACTIVE_NOT_RECRUITING
Wenzhou Dry Age-related Macular Degeneration (AMD) Progression Study
NCT03433885
UNKNOWN
Vision Outcomes Using Quantitative Optical Coherence Tomography Evaluation in Age Related Macular Degeneration
NCT02422160
COMPLETED
Natural History Study of Inherited Retinal Diseases
NCT07085533
RECRUITING
Metabolomics: A Novel Tool for Investigating the Pathogenesis of Age-related Macular Degeneration
NCT04241536
COMPLETED
NA
Brain Connectivity in Age-Related Macular Degeneration
NCT01996215
COMPLETED